Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: A [123I]2β-carbomethoxy-3β-(4- iodophenyl)-tropane single photon emission computed tomography imaging study

Journal of Clinical Psychopharmacology

Volumn 27, Issue 1, 2007, Pages 71-75

  Shang, Yili ^a   Gibbs, Megan A ^a   Marek, Gerard J ^a   Stiger, Thomas ^a   Burstein, Aaron H ^a   Marek, Kenneth ^b   Seibyl, John P ^b   Rogers, Janyce F ^a  

^a PFIZER INC   (United States)

^b INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; CITALOPRAM; DESVENLAFAXINE; DOPAMINE TRANSPORTER; IODINE 123; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADULT; ARTICLE; BRAIN STEM; CONTROLLED STUDY; CORPUS STRIATUM; DIENCEPHALON; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSE INCREASE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUSTAINED DRUG RELEASE; VOMITING;

ADULT; CAPSULES; COCAINE; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; IODINE RADIOISOTOPES; RADIOPHARMACEUTICALS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33846239958     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31802e0017     Document Type: Article

References (27)

1. Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry. 2001;62:869-877.
2. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234-241.
3. Thase ME. Achieving remission and managing relapse in depression. J Clin Psychiatry. 2003;64(suppl 18):3-7.
4. Thase ME. Evaluating antidepressant therapies: remission as the optimal outcome. J Clin Psychiatry. 2003;64(suppl 13):18-25.
5. Thase ME. Effectiveness of antidepressants: comparative remission rates. J Clin Psychiatry. 2003;64(suppl 2):3-7.
6. Demitrack MA. Can monoamine-based therapies be improved? J Clin Psychiatry. 2002;63(suppl 2):14-18.
7. Skolnick P, Popik P, Janowsky A, et al. "Broad spectrum" antidepressants: is more better for the treatment of depression? Life Sci. 2003;73:3175-3179.
8. Skolnick P. Beyond monoamine-based therapies: clues to new approaches. J Clin Psychiatry. 2002;63(suppl 2):19-23.
9. Beer B, Stark J, Krieter P, et al. DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile. J Clin Pharmacol. 2004;44:1360-1367.
10. Charney DS. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry. 1998;59(suppl 14):11-14.
11. 11C]DASB positron emission tomography study. Am J Psychiatry. 2004;161:826-835.
12. (11)C]DASB PET imaging study. Am J Psychiatry. 2001;158:1843-1849.
13. Kugaya A, Seneca NM, Snyder PJ, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology. 2003;28:413-420.
14. (123)I]beta-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. Neuropsychopharmacology. 2005;30:996-1005.
15. Maj J, Rogoz Z. Pharmacological effects of venlafaxine, a new antidepressant, given repeatedly, on the alpha 1-adrenergic, dopamine and serotonin systems. J Neural Transm. 1999;106:197-211.
16. O'Hanlon JF, Robbe HW, Vermeeren A, et al. Venlafaxine's effects on healthy volunteers' driving, psychomotor, and vigilance performance during 15-day fixed and incremental dosing regimens. J Clin Psychopharmacol. 1998;18:212-221.
17. Nicholson AN, Pascoe PA. Dopaminergic transmission and the sleep-wakefulness continuum in man. Neuropharmacology. 1990;29:411-417.
18. Steinberg M. Structured Clinical Interview for DSM-IV Dissociative Disorders (SCID-D). Washington, DC: American Psychiatric Press; 1994.
19. Owens MJ, Morgan WN, Plott SJ, et al. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther. 1997;283:1305-1322.
20. Venlafaxine [package insert]. Philadelphia, PA Wyeth; 2005.
21. Gabrielsson J, Weiner D. Pharmacokinetic/pharmacodynamic data analysis: concepts and applications. Stockholm, Sweden: Swedish Pharmaceutical Press; 2000.
22. 123I]beta-CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. Nucl Med Biol. 1993;20:597-606.
23. 123I] beta-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab. 1994;14:982-994.
24. Pirker W, Asenbaum S, Kasper S, et al. beta-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. J Neural Transm Gen Sect. 1995;100:247-256.
25. (11)C]-DASB binding to the human serotonin transporter: modeling strategies. J Cereb Blood Flow Metab. 2001;21:1342-1353.
26. Seibyl JP, Wallace E, Smith EO, et al. Whole-body biodistribution, radiation absorbed dose and brain SPECT imaging with iodine-123-beta-CIT in healthy human subjects. J Nucl Med. 1994;35:764-770.
27. Suhara T, Sudo Y, Yoshida K, et al. Lung as reservoir for antidepressants in pharmacokinetic drug interactions. Lancet. 1998;351:332-335.